|
1
|
De Cock D and Hyrich K: Malignancy and
rheumatoid arthritis: Epidemiology, risk factors and management.
Best Pract Res Clin Rheumatol. 32:869–886. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wasserman AM: Diagnosis and management of
rheumatoid arthritis. Am Fam Physician. 84:1245–1252.
2011.PubMed/NCBI
|
|
3
|
Wasserman A: Rheumatoid arthritis: Common
questions about diagnosis and management. Am Fam Physician.
97:455–462. 2018.PubMed/NCBI
|
|
4
|
McInnes IB and Schett G: The pathogenesis
of rheumatoid arthritis. N Engl J Med. 365:2205–2219.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Croia C, Bursi R, Sutera D, Petrelli F,
Alunno A and Puxeddu I: One year in review 2019: Pathogenesis of
rheumatoid arthritis. Clin Exp Rheumatol. 37:347–357.
2019.PubMed/NCBI
|
|
6
|
Udalova IA, Mantovani A and Feldmann M:
Macrophage heterogeneity in the context of rheumatoid arthritis.
Nat Rev Rheumatol. 12:472–485. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rana AK, Li Y, Dang Q and Yang F:
Monocytes in rheumatoid arthritis: Circulating precursors of
macrophages and osteoclasts and, their heterogeneity and plasticity
role in RA pathogenesis. Int Immunopharmacol. 65:348–359.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang QQ, Birkett R, Doyle R, Shi B,
Roberts EL, Mao Q and Pope RM: The role of macrophages in the
response to TNF inhibition in experimental arthritis. J Immunol.
200:130–138. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
de La Forest Divonne M, Gottenberg JE and
Salliot C: Safety of biologic DMARDs in RA patients in real life: A
systematic literature review and meta-analyses of biologic
registers. Joint Bone Spine. 84:133–140. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Massalska M, Maslinski W and Ciechomska M:
Small molecule inhibitors in the treatment of rheumatoid arthritis
and beyond: Latest updates and potential strategy for fighting
COVID-19. Cells. 9(1876)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ternant D, Bejan-Angoulvant T, Passot C,
Mulleman D and Paintaud G: Clinical pharmacokinetics and
pharmacodynamics of monoclonal antibodies approved to treat
rheumatoid arthritis. Clin Pharmacokinet. 54:1107–1123.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Accortt NA, Bonafede MM, Collier DH, Iles
J and Curtis JR: Risk of subsequent infection among patients
receiving tumor necrosis factor inhibitors and other
disease-modifying antirheumatic drugs. Arthritis Rheumatol.
68:67–76. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lv J, Wu J, He F, Qu Y, Zhang Q and Yu C:
Development of Bruton's tyrosine kinase inhibitors for rheumatoid
arthritis. Curr Med Chem. 25:5847–5859. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hendriks RW, Yuvaraj S and Kil LP:
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev
Cancer. 14:219–232. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Norman P: Investigational Bruton's
tyrosine kinase inhibitors for the treatment of rheumatoid
arthritis. Expert Opin Investig Drugs. 25:891–899. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hsu J, Gu Y, Tan SL, Narula S, DeMartino
JA and Liao C: Bruton's Tyrosine Kinase mediates platelet
receptor-induced generation of microparticles: A potential
mechanism for amplification of inflammatory responses in rheumatoid
arthritis synovial joints. Immunol Lett. 150:97–104.
2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Whang JA and Chang BY: Bruton's tyrosine
kinase inhibitors for the treatment of rheumatoid arthritis. Drug
Discov Today. 19:1200–1204. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Di Paolo JA, Huang T, Balazs M, Barbosa J,
Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, et
al: Specific Btk inhibition suppresses B cell- and myeloid
cell-mediated arthritis. Nat Chem Biol. 7:41–50. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wu J, Zhu Z, Yu Q and Ding C: Tyrosine
kinase inhibitors for the treatment of rheumatoid arthritis: Phase
I to Ⅱ clinical trials. Expert Opin Investig Drugs. 28:1113–1123.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Erickson RI, Schutt LK, Tarrant JM,
McDowell M, Liu L, Johnson AR, Lewin-Koh SC, Hedehus M, Ross J,
Carano RA, et al: Bruton's tyrosine kinase small molecule
inhibitors induce a distinct pancreatic toxicity in rats. J
Pharmacol Exp Ther. 360:226–238. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gowhari Shabgah A, Shariati-Sarabi Z,
Tavakkol-Afshari J, Ghasemi A, Ghoryani M and Mohammadi M: A
significant decrease of BAFF, APRIL, and BAFF receptors following
mesenchymal stem cell transplantation in patients with refractory
rheumatoid arthritis. Gene. 732(144336)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li J, Hsu HC and Mountz JD: Managing
macrophages in rheumatoid arthritis by reform or removal. Curr
Rheumatol Rep. 14:445–454. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Moura RA, Quaresma C, Vieira AR, Gonçalves
MJ, Polido-Pereira J, Romão VC, Martins N, Canhão H and Fonseca JE:
B-cell phenotype and IgD-CD27- memory B cells are affected by
TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.
PLoS One. 12(e0182927)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schiff M, Combe B, Dörner T, Kremer JM,
Huizinga TW, Veenhuizen M, Gill A, Komocsar W, Berclaz PY, Ortmann
R, et al: Efficacy and safety of tabalumab, an anti-BAFF monoclonal
antibody, in patients with moderate-to-severe rheumatoid arthritis
and inadequate response to TNF inhibitors: Results of a randomised,
double-blind, placebo-controlled, phase 3 study. RMD Open.
1(e000037)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhao G, Liu A, Zhang Y, Zuo ZQ, Cao ZT,
Zhang HB, Xu CF and Wang J: Nanoparticle-delivered siRNA targeting
Bruton's tyrosine kinase for rheumatoid arthritis therapy. Biomater
Sci. 7:4698–4707. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chang BY, Huang MM, Francesco M, Chen J,
Sokolove J, Magadala P, Robinson WH and Buggy JJ: The Bruton
tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune
arthritis by inhibition of multiple effector cells. Arthritis Res
Ther. 13(R115)2011.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Cao Y, Lu G, Chen X, Chen X, Guo N and Li
W: BAFF is involved in the pathogenesis of IgA nephropathy by
activating the TRAF6/NF-κB signaling pathway in glomerular
mesangial cells. Mol Med Rep. 21:795–805. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
O'Neil LJ and Kaplan MJ: Neutrophils in
rheumatoid arthritis: breaking immune tolerance and fueling
disease. Trends Mol Med. 25:215–227. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Calabresi E, Petrelli F, Bonifacio AF,
Puxeddu I and Alunno A: One year in review 2018: Pathogenesis of
rheumatoid arthritis. Clin Exp Rheumatol. 36:175–184.
2018.PubMed/NCBI
|
|
30
|
Boissier MC, Semerano L, Challal S,
Saidenberg-Kermanac'h N and Falgarone G: Rheumatoid arthritis: From
autoimmunity to synovitis and joint destruction. J Autoimmun.
39:222–228. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kurowska-Stolarska M and Alivernini S:
Synovial tissue macrophages: Friend or foe? RMD Open.
3(e000527)2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Thalhamer T, McGrath MA and Harnett MM:
MAPKs and their relevance to arthritis and inflammation.
Rheumatology (Oxford). 47:409–414. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Schett G, Tohidast-Akrad M, Smolen JS,
Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q and
Steiner G: Activation, differential localization, and regulation of
the stress-activated protein kinases, extracellular
signal-regulated kinase, c-JUN N-terminal kinase, and p38
mitogen-activated protein kinase, in synovial tissue and cells in
rheumatoid arthritis. Arthritis Rheum. 43:2501–2512.
2000.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Salojin KV, Owusu IB, Millerchip KA,
Potter M, Platt KA and Oravecz T: Essential role of MAPK
phosphatase-1 in the negative control of innate immune responses. J
Immunol. 176:1899–1907. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shabgah AG, Shariati-Sarabi Z,
Tavakkol-Afshari J and Mohammadi M: The role of BAFF and APRIL in
rheumatoid arthritis. J Cell Physiol. 234:17050–17063.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wei F, Chang Y and Wei W: The role of BAFF
in the progression of rheumatoid arthritis. Cytokine. 76:537–544.
2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lichtenthaler SF: iRHOM2 takes control of
rheumatoid arthritis. J Clin Invest. 123:560–562. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Siggs OM, Xiao N, Wang Y, Shi H, Tomisato
W, Li X, Xia Y and Beutler B: iRhom2 is required for the secretion
of mouse TNFα. Blood. 119:5769–5771. 2012.PubMed/NCBI View Article : Google Scholar
|
